-transparent.png){kind=logo}
The acetylator phenotype was studied in 21 hypertensive patients receiving chronic treatment with dihydralazine and other antihypertensive drugs. Plasma dihydralazine concentrations were measured 6 hours after the morning dose of the drug. There were no significant differences between the slow and fast acetylators 1) in the daily dose of dihydralazine needed, 2) in the concentrations of dihydralazine achieved in plasma, 3) in the dose/concentration-relationship of dihydralazine or 4) in the appearance of side effects. Antinuclear antibodies were found in five patients. Four of them were fast acetylators. The lowest dose/concentration relationship was found in a patient with impaired renal function. According to these results the acetylator phenotype seems to be an unimportant factor in therapy with dihydralazine. More investigation will be needed in order to elucidate the metabolism of dihydralazine.
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
April 1985,
International journal of clinical pharmacology, therapy, and toxicology,
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
January 1985,
European journal of clinical pharmacology,
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
May 1983,
Lancet (London, England),
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
February 1989,
Indian pediatrics,
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
January 1981,
Clinical pharmacokinetics,
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
January 1989,
European journal of clinical pharmacology,
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
January 1989,
Dermatologica,
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
December 1981,
Neuropharmacology,
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
January 1985,
The New England journal of medicine,
E Iisalo, and
T Laine, and
A Lehtonen, and
R Sellman
January 2003,
Advances in experimental medicine and biology,
